scholarly journals DNA microarray based rapid drug susceptibility test for Mycobacterium leprae

2006 ◽  
Vol 75 (3) ◽  
pp. 271-277 ◽  
Author(s):  
Yasuhiko SUZUKI ◽  
Masanori MATSUOKA
Keyword(s):  
Dna Microarray ◽  
Mycobacterium Leprae ◽  
Drug Susceptibility ◽  
Susceptibility Test ◽  
Drug Susceptibility Test

Slide drug susceptibility test for the detection of multidrug-resistant tuberculosis in Bangladesh

2013 ◽  
Vol 19 (5) ◽  
pp. 818-824 ◽  
Author(s):  
Rashed Noor ◽  
Akter Hossain ◽  
Saurab Kishore Munshi ◽  
Farjana Rahman ◽  
S.M.Mostofa Kamal
Keyword(s):  
Drug Susceptibility ◽  
Multidrug Resistant ◽  
Susceptibility Test ◽  
Drug Susceptibility Test ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis

scholarly journals Development of Drug Resistance among Comorbid and Non-Comorbid HIV-Negative Relapsed Cases of Tuberculosis in Lahore, Pakistan

2020 ◽  
Author(s):  
Arslan Ahmed Salam ◽  
Aamer Ikram ◽  
Maha Fatima ◽  
Najma Javed Awan
Keyword(s):  
Drug Resistance ◽  
Drug Susceptibility ◽  
Susceptibility Test ◽  
Rifampicin Resistance ◽  
Drug Susceptibility Test ◽  
Health Crisis ◽  
Mdr Tb ◽  
History Of ◽  
Xpert Assay ◽  
Hiv Negative

Abstract Background: Mycobacterium tuberculosis sometimes become resistant to the drugs that are used to treat it. Drug resistant TB (DR-TB) is spread in the same way as drug susceptible TB. DR-TB is a public health crisis. This study aims to find the pattern of drug resistance and correlations between drug resistance and comorbid/non-comorbid conditions in patients with a relapse of TB. Methodology: A cross-sectional study was conducted among 200 HIV-negative relapsed TB patients from 2016-2017 in Mayo Hospital Lahore. The patients’ sputum samples were tested by Ziehl-Neelsen staining to observe acid-fast bacilli. The demographics and medical history of patients was recorded, who were positive for AFB in their sputum samples. Molecular procedure of Gene-Xpert assay was conducted to detect the presence of MTB and rifampicin resistance in the samples. Whereas, the drug susceptibility test (DST) was conducted on the LJ culture medium containing drugs.Results: Out of 200 relapsed TB cases; 97 were comorbid, 99 were non-comorbid. The most prevalent comorbidities were hypertension (42 cases- 43.3%), diabetes (45 cases-46.4%) and hepatitis B (14 cases-14.4%). Among 97 comorbid patients; 37 worked as laborers, 43 earned less than 20,000 PKR and 23 were found to have a history of imprisonment. Whereas in non-comorbid patients; 20 worked as laborers, 28 earned less than 20,000 PKR and 12 had been in prison before. The Gene-Xpert test detected rifampicin resistance (RR) in 20 comorbid (20.6%) and 33 non-comorbid (33.3%) patients. Whereas, the drug susceptibility test (DST) showed that 22 comorbid (22.7%) and 33 non-comorbid (33.3%) patients were RR. A contrast was seen in the results of Gene-Xpert and DST; Gene-Xpert detected 3 cases of RR-negative whereas the same 3 cases were found to be RR-positive on DST. Only 1 case was RR-positive on Gene-Xpert but RR-negative on DST. 17 comorbid patients (17.5%) were diagnosed with MDR-TB and 5 (5.2%) with XDR-TB. Whereas, in non-comorbid patients, there were 26 cases of MDR-TB (26.3%) and 5 cases of XDR-TB (5.1%). There were 2 patients (2.1%) resistant to all drugs.Conclusion: There was a deviation in the results of molecular Gene-Xpert assay compared to the conventional culture methods. Drug resistance was relatively higher in non-comorbid patients than comorbid patients, however, the difference between the two is not very significant.

scholarly journals Survival, Chemotherapy and Chemosensitivity Predicted by CTC Cultured In Vitro of SCLC Patients

2021 ◽  
Vol 11 ◽  
Author(s):  
Lixia Ju ◽  
Juan Yang ◽  
Changyun Zhai ◽  
Shuizhen Chai ◽  
Zhiyi Dong ◽  
...  
Keyword(s):  
Objective Response ◽  
Therapy Response ◽  
Drug Susceptibility ◽  
Susceptibility Test ◽  
Therapeutic Regimen ◽  
Second Line ◽  
Drug Susceptibility Test ◽  
Line Therapy ◽  
Potential Marker

PurposeThe prognosis for small cell lung cancer (SCLC) patients receiving later-line treatment is very poor and there is still no standard treatments after the second-line setting. Analyzing the susceptibility of chemotherapeutic drugs with circulating tumor cells (CTCs) cultured in vitro may contribute to optimize the therapeutic regimen. However, so far CTCs have been barely used for studying their chemosensitivity due to the lack of technology to obtain wholly intact and viable CTCs.MethodsBased on a retrospective study of the therapeutic response of 99 patients with unresectable SCLC, the CTC count in 14 SCLC patients was detected before and after chemotherapy to evaluate its role as a potential marker of response. Furthermore, the drug susceptibility of CTCs cultured in vitro obtained from ClearCell FX® System was tested and the therapy response was evaluated.ResultsAll of the 99 patients received the first-line chemotherapy and the objective response rate (ORR) was 74.7%. A total of 36 patients received the second-line therapy and the average duration was 2.6 months, and only 11 cases out of them received the third-line therapy but no one responded. The change of CTC counts was identified to be correlated with therapy response. However all the five SCLC patients who were administered with the drugs according to the drug susceptibility test of CTCs for two cycles underwent progression of disease.ConclusionThe results showed that the responses of chemotherapy are very poor in later lines and the drug susceptibility test using CTCs primary cultured in vitro may not benefit the improvement of therapeutic regimen of SCLC patients.

Sign in / Sign up

Export Citation Format

Share Document